Target General Infomation
Target ID
T96627
Former ID
TTDC00225
Target Name
Macrophage inflammatory protein-2-alpha
Gene Name
CXCL2
Synonyms
Gro-beta; Growth regulatedprotein beta; MIP2-alpha; Macrophage inflammatory protein 2; CXCL2
Target Type
Clinical Trial
Disease Multiple scierosis [ICD9: 340; ICD10: G35]
Function
Produced by activated monocytes and neutrophils and expressed at sites of inflammation. Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. GRO-beta(5-73) shows a highly enhanced hematopoietic activity.
BioChemical Class
Intercrine-alpha family
Target Validation
T96627
UniProt ID
Sequence
MARATLSAAPSNPRLLRVALLLLLLVAASRRAAGAPLATELRCQCLQTLQGIHLKNIQSV
KVKSPGPHCAQTEVIATLKNGQKACLNPASPMVKKIIEKMLKNGKSN
Drugs and Mode of Action
Drug(s) Laquinamod Drug Info Phase 3 Multiple scierosis [536604]
Modulator Laquinamod Drug Info [536604]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Chemokine signaling pathway
NF-kappa B signaling pathway
NOD-like receptor signaling pathway
TNF signaling pathway
Salmonella infection
Legionellosis
NetPath Pathway IL-7 Signaling Pathway
IL1 Signaling Pathway
IL4 Signaling Pathway
TNFalpha Signaling Pathway
IL5 Signaling Pathway
PANTHER Pathway CCKR signaling map ST
Reactome Chemokine receptors bind chemokines
G alpha (i) signalling events
WikiPathways Cytokines and Inflammatory Response
Spinal Cord Injury
GPCR ligand binding
GPCR downstream signaling
References
Ref 536604Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9.
Ref 536604Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.